Project Details
Description
This study provided novel knowledge about STING1-mediated cell death upon the treatment of PARP inhibitor. The combination of Olaparib and STING1 activators may enhance drug efficacy. In addition, targeting the STING1 pathway may serve as a novel therapeutic strategy to overcome Olaparib resistance.
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/23 → 6/30/24 |
Keywords
- castration-resistant prostate cancer
- PARP inhibitor
- CRISPR gene editing
- therapy resistance
- epigenetic regulation
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.